source
- BioMarin signs new deal for early-stage bone disease assetBioMarin recently halted development of a rare disease drug that it had acquired in a $270 million transaction. Within a week, the company announced another deal to acquire an early‑stage asset aim…
- Biden-era law, not Trump, drives 2026 drop in brand-drug list pricesList prices for brand-name drugs fell sharply in 2026, marking a notable decline from previous years. Industry experts attribute the reduction primarily to a law enacted during the Biden administr…